Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 2015

View Archived Issues

Novel markers of poor prognoses in lung adenocarcinoma

Verubecestat shows promising results as a BACE1 inhibitor

Improving methods to detect genetic variants in NSCLC

Phylogica and PhoreMost to identify small-molecule cancer drugs

Merck & Co. reports BACE1/BACE2 inhibitors

Compugen divulges anti-VSTM5 antibodies

Celprogen discloses in vivo stem cell activator

FDA approves Ethicon's fibrin sealant patch for use in liver surgery

Tricyclo-DNA antisense oligonucleotides are efficacious in mouse models of DMD

European orphan drug designation for Trappsol Cyclo transferred to MNE

Characterization of BI-409306, a PDE9 inhibitor in early-stage clinical trials

MetrioPharm receives approval to begin clinical development of MP-1032

Alligator Bioscience announces phase I trial of ADC-1013 in advanced solid tumors

Tasly Pharmaceutical patents clopidogrel derivatives

Beijing Hanmi Pharmaceutical reports BTK and/or JAK3 inhibitors

Calitor Sciences develops PI3Kdelta inhibitors

Bristol-Myers Squibb describes mGlu2 receptor PAMs

Portola Pharmaceuticals reports topline data from phase III ANNEXA-A trial

Enrollment begins in phase I/II study of ADXS-PSA in combination with Keytruda

FDA grants breakthrough therapy designation to DBV Technologies' peanut allergy treatment

Shire discloses results from first of three phase II trials of LUM-001 in Alagille syndrome

GNE-309 - a novel BTK inhibitor for the treatment of rheumatoid arthritis

Avastin approved in E.U. for treatment of advanced cervical cancer

DARPA selects Inovio Pharmaceuticals to lead Ebola virus consortium

FDA accepts ArmaGen's IND application for Hurler syndrome therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...